EntryPoint Capital LLC Invests $435,000 in Integer Holdings Co. (NYSE:ITGR)

EntryPoint Capital LLC bought a new stake in Integer Holdings Co. (NYSE:ITGR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,280 shares of the medical equipment provider's stock, valued at approximately $435,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Mather Group LLC. lifted its position in Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 143 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of Integer in the fourth quarter valued at $27,000. R Squared Ltd bought a new position in Integer during the fourth quarter valued at about $44,000. Versant Capital Management Inc grew its holdings in Integer by 98.4% during the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 183 shares during the period. Finally, Principal Securities Inc. raised its position in Integer by 31.2% in the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock worth $85,000 after acquiring an additional 152 shares in the last quarter. Institutional investors own 99.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. KeyCorp boosted their target price on shares of Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Raymond James initiated coverage on shares of Integer in a report on Friday. They set an "outperform" rating and a $145.00 price target on the stock. Citigroup lifted their target price on Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research note on Wednesday, December 11th. Benchmark upped their price objective on shares of Integer from $140.00 to $150.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Truist Financial lifted their target price on shares of Integer from $147.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $148.56.

Remove Ads

Integer Stock Down 0.3 %

Shares of Integer stock traded down $0.41 during midday trading on Friday, reaching $117.09. 310,618 shares of the company's stock traded hands, compared to its average volume of 325,140. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 34.85, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a 52 week low of $107.11 and a 52 week high of $146.36. The company's 50 day simple moving average is $130.47 and its 200 day simple moving average is $132.03. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Equities analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.